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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S130microangiopathy in the setting of candidemia. The 100-day
transplant-related mortality rate was 0% and one patient
died 5 months after ASCT due to neurological complications
without evidence of lymphoma. At a median follow-up of
399 days (range 54-705 days), only one patient, who had
multiply relapsed cutaneous and CNS large cell lymphoma,
had relapsed disease, and only one patient has died. Three
patients had optional lumbar punctures performed 24-36
hours after the ﬁrst dose of high-dose R to determine CSF
levels of R. In those patients, R was present in the lumbar CSF
at concentrations of 343-498 ng/ml. CSF rituximab levels
were about 0.1% of simultaneously obtained serum concen-
trations. For patients with CNS involvement by NHL,
a regimen of high-dose R with high-dose cytarabine for stem
cell mobilization followed by high-dose R with TBC autolo-
gous stem cell transplantation is feasible. Concentrations of R
measured in the CSF are about 0.1% of that achieved in the
peripheral blood, demonstrating limited penetration past the
blood-brain-barrier. High-dose rituximab in combination
with TBC followed by ASCT shows encouraging clinical
activity and merits further study in patients with CNS NHL.38
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Engraftment syndrome (ES) is an increasingly recognized
complication of AHCT. The clinical features consist of peri-
engraftmentnon-infectious fever, skin rash, diarrhea, hepato-
renal dysfunction or capillary leak. In severe cases, ES is more
analogous to autologous graft-versus host disease (AGVHD).
In this study, we analyze a cohort of 584 consecutive AHCT
recipients for multiple myeloma (MM) or lymphoma at our
center between 2002 and 2010 to determine risk factors asso-
ciated with ES/AGVHD. Median follow-up was 49 months. To
our knowledge, this is the largest series to report on this topic.
The median age was 57 yrs with 355 males. The under-
lying disease was MM in 71% (n¼415); non-Hodgkin
lymphoma (NHL) in 20% (n¼116); and Hodgkin lymphoma
(HL) in 9% (n¼54).
Patients were identiﬁed with ES according to Maiolino
and Spitzer criteria. A total of 131 patients (22%) developed
ES (n¼104) or biopsy proven AGVHD (n¼27). Onset of clinical
ES/AGVHD was between 3 days prior and up to 10 days after
neutrophil engraftment; at a median of 12 days after AHCT.
Clinical features were fever (90%), skin rash (50%), diarrhea
(68%) and LFT abnormalities (23%). The majority (93%) were
treated with corticosteroids, achieving a complete response.
The median duration of steroids was 12 (2-151) days. Seven
patients required additional immunosuppressive treatment.
Six deaths were attributable to ES/AGVHD. Patients with ES
had longer hospital stays with a median admission of 15 days
in those without ES/AGVHD (7-58) and 17 days (12-157) in
those with ES/AGVHD (p<0.001).
By univariate analysis, ES/AGVHD was more associated
with MM and increasing patient age. Multivariate analyses
were performed stratiﬁed by disease type MM or lymphoma.
ES was signiﬁcantly more common after 2005 in the era of
novel anti-myeloma agents with ES/AGVHD only occurring in7.5% before 2005 and in 22.6% during and after 2005
(p0.001).
In multivariate models, NHL/HL was associated with
lower risk of developing ES/AGVHD (HR¼0.36, P ¼ .0003)
while age >60 yrs was associated with higher risk (HR ¼
1.94; P ¼ .001). Considering MM patients only, pre-AHCT
exposure to Lenalidomide (HR¼1.89; P¼ .005) or Bortezomib
(HR¼2.6;P < .0001) and age >60 yrs (HR¼ 2; P ¼ .001) were
strongly associated with ES/AGVHD. There was no difference
in TRM, relapse, PFS or OS between the two groups sug-
gesting a lack of graft-versus-myeloma effect with ES/
AGVHD.
In conclusion, these data demonstrate that the increasing
incidence of ES/AGVHD in recent years maybe associated
with novel agent induction in MM. Novel agent induction
may affect T cell subpopulations in the infused graft capable
of mediating ES/AGVHD.
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Although, MM remains the most common indication for
ASCT in the US, a controversy exists about the timing of ASCT.
Since earlyASCT (eASCT) versus delayedASCT (dASCT) results
in similar progression free survival (PFS) and overall survival
(OS), economic assessment of both strategies would help in
MM treatment paradigm. A decision tree was developed to
compare the outcomes of ASCT in newly diagnosed trans-
plant eligible MM patients after chemotherapy with lenali-
domide. The survival data was obtained from our published
data on eASCT versus dASCT in MM patients who underwent
initial therapy with dexamethasone + immunomodulatory
agents (IMiDs). The initial decision node on the decision tree
model was dichotomized based on the cutoff of 12 months
(m) for eASCT versus dASCT. The probabilities of events
during the length of follow up (60m) period which formed
our base case (BC) are: (a) eASCT cohort: IMiD for median of
6m> ASCT>median 30m to relapse (and drug free interval)
>median therapy of 24m for relapsedMM; (b) dASCTcohort:
